Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancerKongsted, Per; Svane, Inge M.; Lindberg, Henriette; Bisbjerg, Rasmus; Daugaard, Gedske; Sengeløv, LisaAnti-Cancer Drugs: August 2016 - Volume 27 - Issue 7 - p 695–701 doi: 10.1097/CAD.0000000000000375 CLINICAL REPORTS Buy Abstract Author InformationAuthors Article MetricsMetrics To compare treatment outcomes in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel (CA) as second-line or third-line therapy in the everyday clinical setting. Charts from 94 patients treated with CA as second-line (n=28) or third-line therapy (n=66) were evaluated. Common Terminology Criteria for Adverse Events were used to register grade 3–4 nonhematological toxicity during treatment with CA. Baseline metastatic castration-resistant prostate cancer-related prognostic factors, duration of therapy, and maximum prostate-specific antigen (PSA) percentage change were registered during treatment with CA and previous/subsequent novel androgen receptor targeting therapies. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method. A median of 6 versus 5 treatment cycles was administered in patients treated with second-line and third-line CA (P=0.483). Events with grade 3–4 nonhematological toxicity were equally distributed in the two groups (32 vs. 35%, P=0.80). PSA responses were observed in 46 and 17% of patients treated with second-line and third-line CA (P=0.002). PFS (5.5 vs. 3.3 months, P=0.087, log rank) and OS (18.3 vs. 11.4 months, P=0.003, log rank) was longer in patients treated with second-line CA. OS measured from second-line abiraterone acetate/enzalutamide was similar (18.0 months) to second-line CA (P=0.883, log rank). Treatment-related toxicity was independent of CA being administered as second-line or third-line therapy. Although PFS and the frequency of PSA responders favored patients treated with second-line CA, one treatment sequence could not be considered superior to the other in this study. Departments of aOncology bUrology, Herlev Hospital, University of Copenhagen, Herlev cDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Correspondence to Per Kongsted, MD, Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75 2730 Herlev, Denmark Tel: +45 3868 9081; fax: +45 3868 4153; e-mail: firstname.lastname@example.org Received March 10, 2016 Accepted April 13, 2016 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.